# Alumis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alumis

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.alumis.com
- Total disclosed funding: $192M
- Latest round: Series C (Mar 4, 2024)
- Investors on record: 12

## About

Based in California, US, and founded in 2021 by founder June Lee, Alumis Inc., formely known as Esker Therapeutics Inc. operates as a precision medicine company that focuses on the discovery, development, and treatment of autoimmune disorders. In March 2024, Alumis Inc. raised USD 259 million in series C funding co-led by Foresite Capital, Samsara BioCapital, and VenBio Partners, with participation from Ally Bridge Group, Cormorant Asset Management, HBM Partners, Lilly Asia Ventures, Matrix Capital Management, Nextech, Omega Funds, Piper Heartland Healthcare Capital, and SR One. As of January 2022, the company is led by CEO Martin Babler.

Esker Therapeutics is a Foresite Labs-incubated precision medicine company that is reworking the discovery, development, and treatment of autoimmune disorders and comprises curated genetic, clinical, and health records data, a systems immunology toolkit for prospective data collection, and tools for building patient registries.
The company's pipeline, ESK-001, also known as a TYK2 inhibitor, is currently in clinical development for psoriasis with multiple other indications. TYK2 is a gene that encodes a member of the tyrosine kinase and, more specifically, the Janus kinases (JAKs) protein families and a central node in the signalling pathways of cytokines known as key mediators of inflammation and autoimmune diseases. 

The company plans to use its Series B funding from January 2022 to continue to advance its pipeline, led by ESK-001.

## Funding rounds

- Series C, Mar 4, 2024, $130M — HBM Partners, SR One, Lilly Asia Ventures, Nextech, Omega Funds, Foresite Capital, VenBio, Cormorant Asset Management, Matrix Capital Management, Ally Bridge Group, Samsara BioCapital, Piper Heartland Healthcare Capital
- Series A, May 5, 2021, $62M — Foresite Capital

## Investors

- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series A, Series C
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series C
- SR One (https://capitalatlas.ai/funds/sr-one) — Series C
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series C
- Nextech (https://capitalatlas.ai/funds/nextech) — Series C
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series C
- VenBio (https://capitalatlas.ai/funds/venbio) — Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series C
- Matrix Capital Management — Series C
- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series C
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series C
- Piper Heartland Healthcare Capital — Series C